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Abstract
Background: Although a variety of treatment guidelines for Type 2 diabetes patients are available, a majority of
patients does not achieve recommended targets. We aimed to characterise Type 2 diabetes patients from Swiss
primary care who miss HbA1c treatment goals and to reveal factors associated with the poorly controlled
HbA1c level.
Methods: Cross-sectional study nested within the cluster randomised controlled Chronic Care for Diabetes study.
Type 2 diabetes patients with at least one HbA1c measurement ≥7.0 % during the last year were recruited from
Swiss primary care. Data assessment included diabetes specific and general clinical measures, treatment factors and
patient reported outcomes.
Results: 326 Type 2 diabetes patients from 30 primary care practices with a mean age 67.1 ± 10.6 years participated
in the study. The patients’ findings for HbA1c were 7.7 ± 1.3 %, for systolic blood pressure 139.1 ± 17.6 mmHg, for
diastolic blood pressure 80.9 ± 10.5 mmHg and for low density lipoprotein 2.7 ± 1.1. 93.3 % of the patients suffered
from at least one comorbidity and were treated with 4.8 ± 2.1 different drugs. No determining factor was
significantly related to HbA1c in the multiple analysis, but a significant clustering effect of GPs on HbA1c could
be found.
Conclusions: Within our sample of patients with poorly controlled Type 2 diabetes, no “bullet points” could be
pointed out which can be addressed easily by some kind of intervention. Especially within this subgroup of
diabetes patients who would benefit the most from appropriate interventions to improve diabetes control, a
complex interaction between diabetes control, comorbidities, GPs’ treatment and patients’ health behaviour seems
to exist. So far this interaction is only poorly described and understood.
Trial registration: Current Controlled Trials ISRCTN05947538.
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Background
Type 2 diabetes is one of the most common chronic dis-
eases with an increasing prevalence worldwide [1]. A re-
cently published study estimated the prevalence of Type
2 diabetes in Switzerland between 5.7 % and 7.0 % [2].
This chronic condition is a major challenge for the
health care system and especially for primary care, where
most of the patients are treated. In the long term, Type
2 diabetes results in serious vascular, nephrological,
neurological and ophthalmological complications [3-5].
Today, a variety of treatment approaches, especially
pharmaceutical drugs, are available which enable physi-
cians to achieve the recommended treatment goals in
nearly all patients [6,7]. But in reality, a majority of
patients does not achieve recommended treatment tar-
gets, neither regarding the HbA1c level, nor the recom-
mendations regarding blood pressure and lipid level.
The so called “evidence-performance-gap”, describing
the gap between evidence from large clinical trials and
the daily performance in real life is remarkable, even if
some recent studies suggested that a very low HbA1c
level might not be beneficial for all patients. Undoubt-
edly, diabetic patients take the largest benefit from
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appropriate control of blood sugar, blood pressure and
lipid level [8-12].
In this study we focused on primary care patients
missing the actual HbA1c treatment targets. Our aim
was to characterise these patients and to reveal possible
factors associated with the poorly controlled HbA1c
level. These factors could be possible targets in tailored
interventions aiming at poorly controlled Type 2 dia-
betes patients.
Methods
Study design
The data on which this cross-sectional study is based
were collected within the baseline assessment of
patients participating in the cluster randomised con-
trolled Chronic Care for Diabetes study (CARAT,
ISRCTN05947538) [13]. According to a power calcula-
tion for cluster randomised trials, we planned to recruit
28 GPs who subsequently included 12 patients suffering
from poorly controlled Type 2 diabetes. About 800 ran-
domly selected GPs from the Eastern part of Switzerland
were invited to an information meeting on the study.
Additionally, the project was presented in several quality
circle meetings in doctors’ networks. Detailed informa-
tion on the study is given elsewhere [13]. The study
protocol has been approved by the ethics committee of
the Kanton Zurich and received an unrestricted positive
vote on 25.01.2010.
Patients
Eligible patients were identified through the GPs registry
based on laboratory and received an initial letter by the
GPs containing information on the study. All patients
were included in consecutive order of appearance in the
practice, regardless the reason for the current encounter.
The inclusion criteria to participate in the study were
adulthood, a diabetes mellitus Type 2 diagnosis (initially
diagnosed with a Fasting Glucose in blood plasma >7.0
mmol / 126 mg/dl) and at least one HbA1c measure-
ment ≥7.0 % during the last year. The latter criterion
was formulated because the aim of CARAT was to re-
duce the primary outcome HbA1c with the intervention
by 0.5 % points considering the current recommenda-
tions (HbA1c = 6.5 %) at study onset [7]. Exclusion cri-
teria were insufficient language skills to read and
understand informed consent, patient information and
the questionnaires, practice contact for emergencies only
(e.g. no continuous patient-doctor relationship) and a
life expectancy less than six months due to oncological
or other severe diseases.
Measures and data collection
After the patients gave their written informed consent, a
questionnaire was filled out by the GPs and the practice
nurses for each participant containing questions on diag-
nostic findings, comorbidities and diabetes associated
complications (retinopathy, nephropathy and peripheral
vascular disease), current medication, number of consul-
tations during the past year and an estimation regarding
the patient’s compliance using a 4-point scale (1 = very
good, 4 = very bad, used previously [14]). Current clinical
and laboratory measures such as HbA1c, blood pressure,
fasting blood glucose, body weight, LDL, HDL, total
cholesterol and pulse were assessed by the practice team
using point-of-care laboratory analysis and/or external
laboratories. Creatinine clearance was calculated by sim-
plified MDRD and Cockcroft formula.
A second questionnaire was filled out by the patients
containing questions about patients’ characteristics,
smoking behaviour, Patient Health Questionnaire short
form PHQ-9 [15], Medical Outcomes Study 36-Item
Short-Form Survey (SF-36) [16] and Patient Assessment
of Chronic Illness care (PACIC) [17,18].
The PHQ-9 [15] contains 9 items which correspond to
the DSM-IV criteria for major depression. The items are
scored using a Likert Type scale ranging from 0 (=not at
all) to 3 (=almost every day). A total depressive summary
score is constructed, and the following interpretation is
suggested by the authors: 0-4 = no, 5-9 = light, 10-14
=moderate, 15-19 = severe, 20-27 =most severe depres-
sive disorder with a recommended cut-off score of 10
points for major depression. The PHQ-9 has been
proven to be a valid and reliable tool to assess depres-
sion, has already been used in previous studies in pri-
mary care [19,20] and was recently validated in diabetes
patients [21].
The generic quality of life instrument SF-36 assesses
physical and mental functioning and comprises the eight
domains physical functioning, physical role (role limita-
tion due to physical problems), bodily pain, general
health, vitality, social functioning, emotional role (role
limitation due to emotional problems) and mental
health. For all these multi-item domains, the raw sum-
mary scores were transformed into a 0 to 100 scale
(higher scores indicate better health status) according to
the SF-36 manual [22]. The physical component sum-
mary scale (PCS) and mental component summary scale
(MCS) were calculated by considering the mean, SD and
regression coefficients from the proposed American
norm population of the SF-36 manual [22].
The PACIC has been developed to assess congruency
of provided health care to the Chronic Care Model
(CCM) [23-26]. It is organized according to the key ele-
ments of the CCM and assesses the behaviour of profes-
sionals and practice teams from a patient’s perspective.
It contains 20 items which reflect the 5 scales patient ac-
tivation, delivery system design/decision support, goal
setting/tailoring, problem solving/contextual and follow-
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up/coordination. The items are scored on a 5-point
Likert scale, ranging from 1 (almost never) to 5 (al-
most always). Recently, a German version of the
PACIC has been validated in a sample of osteoarthritis
patients [18].
The GPs created a list with the participants and allo-
cated a code to each patient. Both questionnaires were
marked with this patient code and sent to the University
in a stamped envelope independently by the patients and
practice teams. The University had no access to the
patients’ names, anonymity was therefore ensured.
Statistical analysis
Continuous variables are presented as means and stand-
ard deviations (SD), categorical data as frequencies and
percentages. Bivariate association measurements be-
tween the HbA1c and continuous variables were con-
ducted using Pearson correlations, between HbA1c and
categorical variables using t-tests and one-way ANOVA
(more than two groups). Multiple regression analysis
was applied to examine the independent association be-
tween HbA1c and patient characteristics. We included
all variables in the regression model that showed a sig-
nificant relationship with HbA1c on a 10 % level in the
bivariate analyses and, in addition, could be interpreted
as potential determinants of HbA1c in terms of content.
We supplemented the model with potential determi-
nants of HbA1c according to the literature which were
not significant in the bivariate analyses. We further used
multilevel regression analysis with the GP as cluster
level, thus taking into account that patient observations
are not independent, i.e. observations in one cluster tend
to be more similar to each other than to individuals in
the rest of the sample. The amount of clustering (i.e. the
variation that is explained by the GP level) was assessed
by calculating the intraclass correlation coefficient (ICC)
ranging from 0 % (i.e. no evidence for clustering) to 100
% (i.e. all the variation in HbA1c difference is explained
on GP level). A two-sided alpha of 0.05 was set as level
of significance for all comparisons. All analyses were cal-
culated using STATA statistical package, version 11.2
(Stata Incorporation, College Station, TX, USA) or SPSS
Statistics 19.0 software.
Results
GP characteristics
30 GPs from the German speaking part of Switzerland
participated in the study. Their mean age was 50.7 ± 7.2
years and 27 (90 %) were male. 10 (33.3 %) GPs worked
in single handed and 20 (66.7 %) in group practices. 17
(56.7 %) were member of a doctor’s network (“Aerzte-
netz”) whereas 13 (43.3 %) were not.
Patient and treatment characteristics of the sample
Patient characteristics and clinical measures
Between February and May 2010 326 patients (7–13 per
practice) with poorly controlled Type 2 diabetes were
enrolled into the study. 57.4 % were male with a mean
age of 67.1 ± 10.6 years. 11.5 % currently smoked and
41.1 % were former smokers. The majority (57.6 %) had
a positive family history of Type 2 diabetes (1st grade)
and their diabetes has been diagnosed 9.9 ± 7.6 years ago
on average. The mean HbA1c level was 7.7 ± 1.3 %, the
mean systolic blood pressure 139.1 ± 17.6 mmHg, the
mean diastolic blood pressure 80.9 ± 10.5 mmHg and the
mean low density lipoprotein (LDL) 2.7 ± 1.1. On aver-
age, patients had eight consultations at the GPs in the
past year and their compliance was mostly rated by the
GPs as “good” (46.0 %) and “very good” (33.6 %)
(Table 1). 16.9 % of the patients achieved the recom-
mended targets [7] regarding blood pressure (<130/80),
49.5 % regarding LDL-cholesterol (<2.6 mmol/l).
Comorbidities, diabetes associated complications and
medication
93.3 % of the patients suffered from at least one comor-
bidity, more than half of the patients had three or more
comorbidities. The most frequent comorbidity was arter-
ial hypertension (71.3 %), followed by hyperlipidemia
(66.7 %) and adipositas (53.1 %) (Table 2). Diabetes asso-
ciated microvascular complications were diagnosed in
8.6 % of the patients; most frequently diabetic retinop-
athy (5.3 %), followed by peripheral vascular disease (3.1
%) and diabetic nephropathy (1.8 %).
On average, patients were treated with 4.8 different
drugs. Almost all (96.6 %) received an antidiabetic med-
ical therapy; more frequently an oral medication (88.2
%) than insulin (31.8 %), in 23.8 % a combination of the
two. Additionally, 76.2 % of the patients received an
antihypertensive agent, 55.4 % antiplatelet therapy, 56.3
% lipid-lowering therapy and 11.5 % antidepressants
(Table 3).
Patient reported outcomes
Means and SD of SF-36, PACIC and PHQ-9 are pre-
sented in Table 4. According to the PHQ-9, 16.2 % of
the patients met cut-off criteria for major depression.
Associations with HbA1c
In the bivariate analysis, following factors which fulfilled
our criteria for the regression model were significantly
associated with a higher HbA1c (Tables 1, 2, 3 and 4):
age (younger), compliance (lower), antidiabetic therapy
(none: lowest, with insulin higher, combined highest),
BMI (higher) and SF-36 domain vitality (lower). Except
for antidiabetic therapy, we did not include any pharma-
cological treatment into the multiple model.
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Table 1 Patient characteristics, clinical measures and association with HbA1c
Mean± SD or n (%) Association with HbA1c1)
Coefficient P-value
Anthropometrics and sociodemographics
Age (years) 67.1 ± 10.6 -0.167 0.003 a)
Male gender (n, %) 187 (57.4) 0.675 b)
Nationality Swiss (n, %) 291 (91.8) 0.228 b)
Living together with partner/family (n, %) 246 (78.3) 0.392 b)
Still working (n, %) 100 (32.2) 0.249 b)
Education (years) 11.6 ± 3.2 -0.027 0.632 a)
Smoking status 0.780 c)
Current smoker (n, %) 36 (11.5)
Former smoker (n, %) 129 (41.1)
Never smoker (n, %) 149 (47.4)
Diabetes variables
Duration of diabetes (years) 9.9 ± 7.6 0.019 0.740 a)
Family history of Type 2 diabetes (n, %) 186 (57.6) 0.987 b)
Glycated haemoglobin (HbA1c, %) 7.7 ± 1.3
Fasting serum glucose (mmol/l) 8.0 ± 2.4 0.472 0.000 a)
Severe hypoglycaemia (≥1, %) 2) 32 (9.8) 0.937 b)
Hyperglycaemic episodes (≥1, %) 2) 19 (5.8) 0.091 b), 4d)
Self monitoring of blood glucose
none (n, %) 65 (19.9) 0.352 b)
daily (≥1) (n, %) 133 (40.8) 0.122 b)
weekly (≥1) (n, %) 101 (31.0) 0.205 b)
monthly (≥1) (n, %) 27 (8.3) 0.707 b)
Foot status (pathological; n, %) 52 (16) 0.105 b)
Peripheral pulse status (pathological; n, %) 97 (29.8) 0.387 b)
Monofilament test (pathological; n, %) 42 (13.5) 0.091 b), 4e)
Vibratory sensation (pathological; n, %) 81 (24.9) 0.735 b)
Annual dilated eye exam
pathological (n, %) 28 (8.7) 0.898 b)
non-pathological (n, %) 194 (60.1) 0.376 b)
not conducted (n, %) 101 (31.2) 0.372 b)
Clinical and laboratory measures
Number of consultations last year 8.07 ± 6.0 -0.051 0.355 a)
Compliance (1 = very good, 4 = very bad) 1.87 ± 0.7 0.161 0.004 a)
0.027 c),3),4f)
very good 109 (33.6)
rather good 149 (46)
rather bad 64 (19.8)
very bad 2 (0.6)
Blood pressure systolic (mmHg) 139.1 ± 17.6 -0.004 0.941 a)
Blood pressure diastolic (mmHg) 80.9 ± 10.5 0.101 0.070 a)
Pulse 73.7 ± 11.9 0.024 0.671 a)
Body-mass index (BMI; kg/m2) 30.6 ± 5.6 0.137 0.013 a)
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Hyperglycaemic episodes, monofilament test and
creatinine-clearance were also not included as they were
judged to be results of HbA1c instead of possible deter-
minants. Variables not included due to colinearity with
model variables were fasting serum glucose, therapy with
insulin, waist circumference and adipositas. Hyperten-
sion, hyperlipidemia and diastolic blood pressure were
not considered because they were represented by the
included variable number of comorbidities (see below).
Based on literature review, we additionally included sex,
duration of diabetes (supposed: longer), living together
with partner/family (supposed: no), smoking status (sup-
posed: current smoking), depression (PHQ summary
score, supposed: higher) and number of comorbidities
(supposed: more). The results of the multiple linear re-
gression are presented in Table 5. No significant
Table 1 Patient characteristics, clinical measures and association with HbA1c (Continued)
Waist circumference (cm) 108.3 ± 12.4 0.105 0.059 a)
Waist-hip ratio (cm/cm) 1.0 ± 0.1 0.006 0.910 a)
Cholesterol (mmol/l)
Total 4.8 ± 1.1 0.069 0.214 a)
Low-density lipoprotein (LDL) 2.7 ± 1.1 0.072 0.196 a)
High-density lipoprotein (HDL) 1.2 ± 0.4 -0.088 0.113 a)
Creatinine (μmol/l) 82.1 ± 26.8 -0.009 0.866 a)
Creatinine-Clearance according to Cockcroft 96.3 ± 47.6 0.108 0.052 a)
1) a) Associations HbA1c with continuous variables by Pearson correlations (coefficient), between HbA1c and categorical variables by b) t-tests and c) ANOVA.
2) In the last 12 months.
3) Compliance categories “rather bad & very bad” categorised because of “very bad” n= 2.
4) HbA1c (%) mean per category of significant t-test and ANOVA results (p< 0.010): d) Hyperglycaemic episodes: yes = 8.5, no = 7.6; e) Monofilament test:
pathological = 7.5, non-pathological = 7.8; f) Compliance: very good= 7.5, rather good= 7.7, rather bad & very bad = 8.0.
Table 2 Comorbidities and association with HbA1c
Mean ± SD or n (%) Association with HbA1c1)
Coefficient P-value
Number of comorbidities 2.66 ± 1.6 -0.041 0.459 a)
≥1 comorbidity (n, %) 304 (93.3) 0.297 b)
0 comorbidities (n, %) 22 (6.7)
1 comorbidity (n, %) 59 (18.1)
2 comorbidities (n, %) 73 (22.4)
3 comorbidities (n, %) 86 (26.4)
≥4 comorbidities (n, %) 86 (26.4)
Hypertension (n, %) 231 (71.3) 0.049 b), 4c)
Hyperlipidemia (n, %) 208 (66.7) 0.097 b), 4d)
Adipositas (n, %)2) 173 (53.1) 0.057 b), 4e)
Obese class I (30 – 34.9) (n, %) 111 (34.1)
Obese class II (35 – 39.9) (n, %) 42 (12.9)
Obese class III (≥ 40) (n, %) 20 (6.1)
Coronary heart disease (n, %) 66 (20.4) 0.350 b)
Depression (n, %) 38 (11.7) 0.855 b)
Asthma / COPD (n, %) 32 (9.8) 0.460 b)
Myocardial infarction (n, %)3) 30 (9.3) 0.530 b)
Heart failure (n, %) 22 (6.8) 0.823 b)
Stroke (n, %)3) 17 (5.2) 0.747 b)
Cancer (n, %)3) 13 (4.2) 0.570 b)
1) a) Associations HbA1c with continuous variables by Pearson correlations, b) between HbA1c and categorical variables by t-tests.
2) BMI≥ 30.
3) Present or history of.
4) HbA1c (%) mean per category of significant t-test and ANOVA results (p< 0.010): c) Hypertension: yes = 7.6, no = 8.0; d) Hyperlipidemia: yes = 7.6, no = 7.8; e)
Adipositas: yes = 7.8, no = 7.6.
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correlation between the investigated determinants and
HbA1c could be found (R squared 0.09). When con-
trolled for clustering effect of GPs, age achieved a sig-
nificant small inverse association with HbA1c in the
multilevel regression analysis (coefficient -.019,
p = 0.033). The clustering effect of GPs on HbA1c was
significant (ICC=12.9 %, p = 0.001).
Discussion
Type 2 diabetes patients with an HbA1c above 7 % trea-
ted in Swiss primary care are multimorbid and do not
achieve current guideline targets regarding cardiovascu-
lar risk factors blood pressure and LDL-cholesterol. In
contrast to our assumption, the regression analysis did
not reveal significant key factors which determine the
HbA1c level. A cluster effect of GPs on HbA1c could be
found.
When comparing the demographics of our study
population to recently published results of treated Type
2 diabetes primary care patients in Europe [27,28] and
specifically in Switzerland [29], the mean age, slightly
higher male percentage, time since diabetes diagnosis
and frequency of diabetes family history were compar-
able. The higher HbA1c of the patients in our sample is
caused by inclusion criteria (at least one HbA1c meas-
urement ≥7 % during the last year). In terms of
Table 3 Medication and association with HbA1c
Mean ± SD or n (%) Association with HbA1c1)
Coefficient P-value
Anitdiabetic therapy 312 (96.6) 0.022 c), 3d)
None (n, %) 12 (3.7)
Only oral (n, %) 2) 208 (64.4)
Only insulin (n, %) 2) 26 (8.0)
Combined (insulin and oral) (n, %) 2) 77 (23.8)
Specific antidiabetic therapies
Insulin (n, %) 103 (31.9) 0.005 b), 3e)
Metformin/Biguanid (%) 254 (78.6) 0.384 b)
Sulfonylurea (n, %) 136 (42.1) 0.764 b)
Gliptine (DPP-III) (n, %) 44 (13.6) 0.425 b)
Glitazone (n, %) 19 (5.9) 0.553 b)
Glinide (n, %) 10 (3.1) 0.160 b)
Incretin mimetic (n, %) 6 (1.9) 0.090 b) 3f)
α-Glucosidase inhibitor (n, %) 4 (1.2) 0.837 b)
Any antihypertensive agent (n, %) 2) 246 (76.2) 0.098 b), 3g)
Diuretics (n, %) 160 (49.5) 0.317 b)
Inhibitor of the angiotensin converting enzyme (ACE-I) (n, %) 156 (48.3) 0.213 b)
Beta-blocker (n, %) 101 (31.3) 0.321 b)
Angiotensin II inhibitor (ARB) (n, %) 70 (21.7) 0.787 b)
Calcium antagonists (n, %) 64 (19.8) 0.135 b)
others (n, %) 4 (1.2) 0.838 b)
Any antiplatelet therapy (n, %) 2) 179 (55.4) 0.700 b)
Aspirin (n, %) 158 (48.9) 0.869 b)
Phenprocoumon (n, %) 21 (6.5) 0.017 b), 3h)
Clopidogrel (n, %) 17 (5.3) 0.505 b)
Any lipid-lowering therapy (n, %) 2) 182 (56.3) 0.005 b), 3i)
Any antidepressants (n, %) 37 (11.5) 0.751 b)
Number of drugs total 4.8 (2.1) -0.052 0.349 a)
1) a) Associations HbA1c with continuous variables by Pearson correlations, between HbA1c and categorical variables by b) t-tests and c) ANOVA.
2) 1 or more drugs possible.
3) HbA1c (%) mean per category of significant t-test and ANOVA results (p< 0.010): d) Anitdiabetic therapy: none = 7.2, only oral = 7.6, only insulin = 7.8, combined
(insulin and oral) = 8.0; e) Insulin: yes = 8.0, no = 7.6; f) Incretin mimetic: yes = 8.6, no = 7.7; g) Any antihypertensive agent: yes = 7.6, no = 8.0; h) Phenprocoumon:
yes = 7.4, no = 7.7; i) Any lipid-lowering therapy: yes = 7.5, no = 7.9.
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cardiovascular risk factors, more patients achieved the
recommended targets [7] regarding LDL-cholesterol
(<2.6 mmol/l) and slightly less regarding blood pressure
(<130/80) as in the mentioned recent studies [27,28].
This is remarkable since only patients with insufficiently
controlled diabetes were included in our study and it
could indicate that GPs focus more on the other cardio-
vascular risk factors when the diabetes is poorly con-
trolled. Interestingly, smoking was less prevalent in our
sample than in the Swiss general population [30], but 41
% were former smokers. More than half of the patients
were obese, being in line with the results of other studies
[28,29,31].
Our patient population was multimorbid, over 90 %
had at least one, 75 % had at least two and more than
half of the patients had three or more comorbid dis-
eases. Multimorbidity of the study sample resulted in
polypharmacy, on average each patient received almost 5
different drugs. Compared to a Spanish primary care
sample [27], the Swiss patients were more frequently
treated with antihypertensive, antiplatelet and lipid-
lowering drugs. Microvascular complications overall, in
particular retinopathy and nephropathy, were much less
prevalent in our patients compared to the Spanish sam-
ple [27]. Interestingly, patients’ compliance rated by the
GPs was mainly classified as very good or good, showing
better ratings compared to results from German primary
care [14]. Even though 16.2 % of the patients met criteria
for major depression according to the PHQ-9 cut-off
score, the PHQ-9 summary score in our sample was
slightly lower than in another recently published study
including diabetes patients [21].
Within our sample of insufficiently controlled diabetes
patients it was not possible to clearly identify factors
associated with HbA1c to reveal possible targets for
interventions. Although compliance did not reveal a sig-
nificant association in the multiple analysis, the bivariate
associations of compliance and the SF-36 subscale vital-
ity with HbA1c are in line with the literature [14,32,33].
The multiple regression model could only explain 9 % of
the overall variation in HbA1c, moreover, no factors
with a relevant or significant contribution could be
Table 4 Patient reported outcomes (SF-36, PACIC and PHQ-9) and association with HbA1c
Mean ± SD or n (%) Association with HbA1c1)
Coefficient P-value
SF-36
Physical functioning 71.3 ± 26.2 0.003 0.961 a)
Physical role 64.8 ± 41.7 -0.056 0.326 a)
Bodily pain 67.8 ± 29.7 -0.006 0.921 a)
General health 61.0 ± 18.1 -0.063 0.271 a)
Vitality 57.3 ± 21.5 -0.105 0.065 a)
Social functioning 79.7 ± 23.8 -0.040 0.483 a)
Emotional role 75.6 ± 39.2 -0.068 0.231 a)
Mental health 73.1 ± 19.7 -0.055 0.337 a)
Physical component summary scale (PCS) 43.9 ± 10.9 -0.020 0.723 a)
Mental component summary scale (MCS) 50.1 ± 11.3 -0.090 0.117 a)
PACIC summary score 3.18 ± 0.85 -0.041 0.491 a)
Patient activation 3.83 ± 1.13 -0.037 0.520 a)
Delivery system/practice design 3.87 ± 0.82 -0.019 0.749 a)
Goal setting/tailoring 2.86 ± 0.98 -0.066 0.262 a)
Problem solving/contextual 3.26 ± 1.22 -0.060 0.306 a)
Follow-up/coordination 2.66 ± 1.05 0.031 0.605 a)
PHQ-9 summary score 5.21 ± 4.76 0.043 0.457 a)
Major Depression overall (10-27) 49 (16.2%) 0.705 b)
No depressive disorder (0-4) 169 (56%) 0.255 b)
Light depressive disorder (5-9) 84 (27.8%) 0.342 b)
Moderate depressive disorder (10-14) 35 (11.6%) 0.953 b)
Severe depressive disorder (15-19) 8 (2.6%) 0.525 b)
Most severe depressive disorder (20-27) 6 (2%) 0.895 b)
1) a) Associations HbA1c with continuous variables by Pearson correlations, b) between HbA1c and categorical variables by t-tests.
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detected. This is in contrast to previous studies which
found e.g. depression to be significantly associated with
higher HbA1c [32,33]. Reasons for these differences may
be related to our focus on patients with poorly con-
trolled diabetes and may also reflect that within this sub-
group of patients, diabetes control is an even more
complex issue with no simple “key targets” to address.
The fact that many of the patients in our sample have
already quit smoking may reflect their contribution to
cardiovascular risk factor control. Since GPs seem
already to focus on treatment of the other relevant car-
diovascular risk factors blood pressure and LDL-
cholesterol, weight control remains as only reasonable
additional intervention. Altogether, these results may re-
flect a complex and so far unexplained interaction
within this specific subgroup between diabetes, comor-
bidities, GPs’ treatment and patients’ health behaviour.
An interesting finding is the fact that a significant
cluster effect occurred, which was higher than in previ-
ous studies [34]. In a recent study of our research group,
investigating hypertension treatment in primary care
(Chmiel et al., 2011, submitted), these cluster effects
could not be identified, indicating that there is more
standardisation in hypertension treatment than in dia-
betes control among GPs.
Since participation in this study was voluntary for all
GPs, some selection bias has to be acknowledged. It is
likely that the sample included merely GPs who were
very interested in the topic diabetes. Furthermore, we
only considered practices in the German part of Switzer-
land; hence regional differences are not considered [29].
Compared to the Swiss GP population statistics, the GPs
participating in our study worked more frequently in
group than single handed practices and were more fre-
quently members of a doctor’s network [35]. Since the
aim of the study was to focus on patients with not opti-
mally controlled diabetes, the results cannot be trans-
ferred to all diabetes patients in primary care. Despite
this selection, the characteristics of our sample were
comparable to other European primary care diabetes
Type 2 samples.
Since we did not restrict the inclusion criteria any fur-
ther, a strength of the study is that we included a wide
spectrum of patients presumably reflecting the “real life”
situation of poorly controlled diabetes patients. In
addition, we were able to collect numerous variables of
patients’ characteristics, clinical data and patient
reported outcomes leading to a comprehensive impres-
sion of this subsample of diabetes Type 2 patients in
Switzerland.
Conclusions
Within our sample of patients with poorly controlled
diabetes, no “bullet points” which can be addressed eas-
ily by some kind of intervention could be pointed out.
Especially within this subgroup of diabetes patients who
would benefit the most from appropriate interventions
to improve diabetes control, a complex interaction be-
tween diabetes control, comorbidities, GPs’ treatment
and patients’ health behaviour seems to exist. So far this
interaction is only poorly described and understood.
More research is needed to define these interactions
within this specific patient group more accurately to
tailor successful interventions.
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